AGILENT TECHNOLOGIES INC
ANYSETrading Snapshot
- Day Range
- $172.85 β $176.76
- 52-Week Range
- $108.35 β $174.77
- Volume
- $2.56B
- Avg Volume
- $2.63B
- Shares Outstanding
- 282.4M
- Next Earnings
- Dec 3, 2026
Fundamentals Snapshot
- Annual Revenue
- $6.95B
- Last Q Revenue
- $1.88B
- P/E Ratio
- 33.9
- P/S Ratio
- 6.6x
- EPS (TTM)
- $5.11
- Dividend Yield
- 0.59%
- Dilution (1yr)
- β2.4%
Why Investors Own A
- βHigh-growth profile β revenue up +54.9% YoY with expanding US Equity exposure.
- βHealthy economics β 43% gross margin and 6% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
AGILENT TECHNOLOGIES INC
AAbout AGILENT TECHNOLOGIES INC
Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers. Complementing these are various laboratory software, information management platforms, data analytics tools, automated and robotic lab systems, dissolution testing equipment, vacuum technology, and general measurement solutions. The Diagnostics and Genomics division offers cutting-edge tools for genetic and diagnostic research. These encompass arrays designed for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression analysis. This segment also provides target enrichment solutions for next-generation sequencing, along with software for genetic data management and interpretation. Furthermore, it synthesizes custom oligonucleotides. Other significant offerings include immunohistochemistry (IHC), in situ hybridization (ISH), hematoxylin and eosin (H&E) staining, and specialized staining solutions. The division also supplies consumables and software essential for quality control analysis of nucleic acid samples, as well as reagents for turbidimetry and flow cytometry applications. A key area of development for this segment is liquid-based pharmacodiagnostics. Agilent CrossLab, the third segment, focuses on providing essential laboratory consumables and services. Its product range features GC and LC columns, products for sample preparation, custom chemical formulations, and various supplies for laboratory instruments. Complementary services include expert support for startup, ongoing operations, training, compliance, Software-as-a-Service (SaaS) offerings, asset management, and professional consultation. The company's products reach customers through a diverse sales network, including direct sales teams, distributors, resellers, manufacturer's representatives, and its e-commerce platforms. Agilent Technologies, Inc. was established in 1999 and maintains its corporate headquarters in Santa Clara, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Ratings
βLatest News & Updates

Agilent Technologies, Inc. (NYSE:A) Stock Now Rated βModerate Buyβ by Sell-Side Brokerages
Shares of Agilent Technologies, Inc. (NYSE: A - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the twenty research firms that are covering the stock, MarketBeat reports. Five analyst

Agilent (A) Up 9.6% Since Last Earnings Report: Can It Continue?
Agilent (A) reported earnings 30 days ago. What's next for the stock?

Agilent Technologies, Inc. (A) Presents at U.S. All Stars Conference Transcript
Agilent Technologies, Inc. (A) Presents at U.S. All Stars Conference Transcript

Agilent Technologies Sees Growth From China, Replacement Cycles and Lab Automation
Agilent Technologies NYSE: A executives outlined continued growth momentum, driven by improving end markets, market-share gains, instrument replacement cycles and operational changes under the company's Ignite transforma

Agilent Launches TapeStationDx Systems for Clinical NGS Sample Quality Control
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the launch of the Agilent 4150 TapeStationDx system, Agilent 4200 TapeStationDx system and Agilent TapeStationDx software, extendi

Bank of America Corp DE Makes New Investment in Agilent Technologies, Inc. $A
Bank of America Corp DE purchased a new stake in Agilent Technologies, Inc. (NYSE: A) in the undefined quarter, according to its most recent filing with the SEC. The fund purchased 1,605,576 shares of the medical researc